From a Parkinson's disease expert: Rasagiline and the Future of Therapy
<p>Abstract</p> <p>John Finberg is a professor of pharmacology at the Faculty of Medicine, Technion – Israel Institute of Technology, home of Israel's two Nobel laureates. He and his colleague Prof. Moussa Youdim were instrumental in the early clinical development of the anti-...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2007-07-01
|
| Series: | Molecular Neurodegeneration |
| Online Access: | http://www.molecularneurodegeneration.com/content/2/1/13 |
| _version_ | 1811316634153910272 |
|---|---|
| author | Lakhan Shaheen E |
| author_facet | Lakhan Shaheen E |
| author_sort | Lakhan Shaheen E |
| collection | DOAJ |
| description | <p>Abstract</p> <p>John Finberg is a professor of pharmacology at the Faculty of Medicine, Technion – Israel Institute of Technology, home of Israel's two Nobel laureates. He and his colleague Prof. Moussa Youdim were instrumental in the early clinical development of the anti-Parkinson drug rasagiline, which gained UK- and EU-marketing authorization in 2005 and US FDA approval in 2006. In our interview, Finberg reflects on his clinical research to develop rasagiline as a commercial drug and its proposed pharmacological mechanisms of action. Moreover, he elucidates the current state of anti-Parkinson drug discovery and offers direction for future research.</p> |
| first_indexed | 2024-04-13T11:52:51Z |
| format | Article |
| id | doaj.art-adfc83ea0a584559b9306b52656d2105 |
| institution | Directory Open Access Journal |
| issn | 1750-1326 |
| language | English |
| last_indexed | 2024-04-13T11:52:51Z |
| publishDate | 2007-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Neurodegeneration |
| spelling | doaj.art-adfc83ea0a584559b9306b52656d21052022-12-22T02:48:00ZengBMCMolecular Neurodegeneration1750-13262007-07-01211310.1186/1750-1326-2-13From a Parkinson's disease expert: Rasagiline and the Future of TherapyLakhan Shaheen E<p>Abstract</p> <p>John Finberg is a professor of pharmacology at the Faculty of Medicine, Technion – Israel Institute of Technology, home of Israel's two Nobel laureates. He and his colleague Prof. Moussa Youdim were instrumental in the early clinical development of the anti-Parkinson drug rasagiline, which gained UK- and EU-marketing authorization in 2005 and US FDA approval in 2006. In our interview, Finberg reflects on his clinical research to develop rasagiline as a commercial drug and its proposed pharmacological mechanisms of action. Moreover, he elucidates the current state of anti-Parkinson drug discovery and offers direction for future research.</p>http://www.molecularneurodegeneration.com/content/2/1/13 |
| spellingShingle | Lakhan Shaheen E From a Parkinson's disease expert: Rasagiline and the Future of Therapy Molecular Neurodegeneration |
| title | From a Parkinson's disease expert: Rasagiline and the Future of Therapy |
| title_full | From a Parkinson's disease expert: Rasagiline and the Future of Therapy |
| title_fullStr | From a Parkinson's disease expert: Rasagiline and the Future of Therapy |
| title_full_unstemmed | From a Parkinson's disease expert: Rasagiline and the Future of Therapy |
| title_short | From a Parkinson's disease expert: Rasagiline and the Future of Therapy |
| title_sort | from a parkinson s disease expert rasagiline and the future of therapy |
| url | http://www.molecularneurodegeneration.com/content/2/1/13 |
| work_keys_str_mv | AT lakhanshaheene fromaparkinsonsdiseaseexpertrasagilineandthefutureoftherapy |